Literature DB >> 8314994

Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination.

M Zrein1, J H Joncas, L Pedneault, L Robillard, R J Dwyer, M Lacroix.   

Abstract

A total of 250 human serum samples were tested for rubella virus immunoglobulin G antibodies by two enzyme immunoassays (EIAs), one using whole rubella virus antigen and the other based on the use of synthetic peptide antigen. The samples were taken from 125 volunteers before and after their immunization with the RA 27/3 rubella vaccine. This study indicates that a synthetic peptide-based EIA can favorably replace current viral lysate-based EIAs to detect rubella virus antibodies following immunization. Because the synthetic peptide used in this newly developed EIA represents a putative neutralization epitope of the rubella virus, it could also be instrumental in determining rubella immune status and in assessing vaccine program efficiency.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314994      PMCID: PMC265571          DOI: 10.1128/jcm.31.6.1521-1524.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic.

Authors:  D M Horstmann; H Liebhaber; G L Le Bouvier; D A Rosenberg; S B Halstead
Journal:  N Engl J Med       Date:  1970-10-08       Impact factor: 91.245

2.  Nonspecific reactions in the hemagglutination inhibition test for detection of rubella antibodies.

Authors:  D B Budzko; D F Jelinek; B W Wilcke
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

3.  Rubella screening and immunization of health care personnel: critical appraisal of a voluntary program.

Authors:  A I Hartstein; M A Quan; M L Williams; H T Osterud; L R Foster
Journal:  Am J Infect Control       Date:  1983-02       Impact factor: 2.918

4.  Congenital rubella syndrome.

Authors:  M Cleary
Journal:  Nurse Pract       Date:  1984-04

5.  Congenital rubella after successful vaccination.

Authors:  L M Bott; D H Eizenberg
Journal:  Med J Aust       Date:  1982-06-12       Impact factor: 7.738

6.  Vaccination of seronegative high-risk populations with attenuated rubella vaccine.

Authors:  M O Lehtinen; K Hakkarainen; P O Leinikki; T K Lehtinen; L M Mattila; E P Helle
Journal:  Ann Clin Res       Date:  1982-12

7.  Diagnosis of postnatal rubella by the enzyme-linked immunosorbent assay for rubella IgM and IgG antibodies.

Authors:  M Vejtorp; E Fanøe; J Leerhoy
Journal:  Acta Pathol Microbiol Scand B       Date:  1979-06

8.  Congenital rubella after maternal reinfection.

Authors:  M Forsgren; G Carlström; K Strangert
Journal:  Scand J Infect Dis       Date:  1979

9.  A rubella epidemic in an unvaccinated pregnant population. I. Screening methods and serological results.

Authors:  K Skaug; J C Ulstrup; B Stray-Pedersen
Journal:  Scand J Infect Dis       Date:  1981

10.  An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain.

Authors:  J S Wolinsky; E Sukholutsky; W T Moore; A Lovett; M McCarthy; B Adame
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  8 in total

1.  Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status.

Authors:  P Cordoba; A Lanoel; S Grutadauria; M Zapata
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

2.  Presence of a neutralizing domain in isolates of rubella virus in Cordoba, Argentina.

Authors:  P Cordoba; S L Grutadauria; C Cuffini; M T Zapata
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

3.  Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals.

Authors:  L A Mitchell; M K Ho; J E Rogers; A J Tingle; R G Marusyk; J M Weber; P Duclos; M L Tepper; M Lacroix; M Zrein
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

4.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

5.  Comparison of novel synthetic peptide-based DETECT-RUBELLA enzyme immunoassays with Enzygnost and IMx for detection of rubella-specific immunoglobulin G.

Authors:  L Pedneault; M Zrein; L Robillard; F Landry; M Lacroix; J Joncas
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

Review 6.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

7.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

8.  Epidemiology of rubella infections in Austria: important lessons to be learned.

Authors:  B Falkensammer; G Walder; D Busch; A Giessauf; M Dierich; R Würzner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-18       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.